Published in Cancer Discov on May 28, 2013
Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell (2014) 1.84
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov (2015) 1.64
Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer (2017) 1.39
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet (2016) 1.16
Molecular pathways and therapeutic targets in lung cancer. Oncotarget (2014) 1.16
STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Res (2016) 0.95
Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9. Proc Natl Acad Sci U S A (2015) 0.92
Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases. J Clin Pathol (2016) 0.90
Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR. Pharmgenomics Pers Med (2015) 0.88
Multidimensional analysis of gene expression reveals TGFB1I1-induced EMT contributes to malignant progression of astrocytomas. Oncotarget (2014) 0.88
LKB1 Tumor Suppressor: Therapeutic Opportunities Knock when LKB1 Is Inactivated. Genes Dis (2014) 0.87
Targeting the LKB1 tumor suppressor. Curr Drug Targets (2014) 0.87
LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells. Oncogene (2015) 0.85
Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss. Oncotarget (2014) 0.83
Update in Lung Cancer 2014. Am J Respir Crit Care Med (2015) 0.79
A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells. BMC Cancer (2014) 0.78
Targeting LKB1 in cancer - exposing and exploiting vulnerabilities. Br J Cancer (2015) 0.78
Role of Epithelial-Mesenchyme Transition in Chlamydia Pathogenesis. PLoS One (2015) 0.78
Plk2 regulates mitotic spindle orientation and mammary gland development. Development (2014) 0.78
Role of CPS1 in Cell Growth, Metabolism, and Prognosis in LKB1-Inactivated Lung Adenocarcinoma. J Natl Cancer Inst (2017) 0.78
Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis. PLoS One (2014) 0.77
NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (PGP1) function. Br J Pharmacol (2016) 0.77
RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies. Acta Biochim Biophys Sin (Shanghai) (2015) 0.76
NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy. Mol Cancer Ther (2015) 0.76
LKB1 promotes cell survival by modulating TIF-IA-mediated pre-ribosomal RNA synthesis under uridine downregulated conditions. Oncotarget (2016) 0.76
MiR-93 Promotes Tumorigenesis and Metastasis of Non-Small Cell Lung Cancer Cells by Activating the PI3K/Akt Pathway via Inhibition of LKB1/PTEN/CDKN1A. J Cancer (2017) 0.75
Energizing the search to target LKB1-mutant tumors. Cancer Discov (2013) 0.75
Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines. Oncotarget (2016) 0.75
Targeting adhesion signaling in KRAS, LKB1 mutant lung adenocarcinoma. JCI Insight (2017) 0.75
The Impact of Genomic Profiling for Novel Cancer Therapy - Recent Progress in Non-Small Cell Lung Cancer. J Genet Genomics (2015) 0.75
Oncogenic mutation profiling in new lung cancer and mesothelioma cell lines. Onco Targets Ther (2015) 0.75
CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells. Nature (2017) 0.75
Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status. Oncotarget (2017) 0.75
Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 49.82
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
LKB1 modulates lung cancer differentiation and metastasis. Nature (2007) 7.80
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res (2002) 7.09
The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol (2011) 6.83
Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev (2009) 6.46
Interactions between deoxyribonucleotide and DNA synthesis. Annu Rev Biochem (1988) 4.79
A positive/negative ion-switching, targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue. Nat Protoc (2012) 3.87
The Lkb1 metabolic sensor maintains haematopoietic stem cell survival. Nature (2010) 3.55
Mammalian deoxyribonucleoside kinases. Pharmacol Ther (1995) 3.31
How nucleotide excision repair protects against cancer. Nat Rev Cancer (2001) 3.29
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther (2008) 3.07
Cell polarity in development and cancer. Nat Cell Biol (2007) 2.45
Thymine metabolism and thymineless death in prokaryotes and eukaryotes. Annu Rev Microbiol (1998) 2.26
Somatic LKB1 mutations promote cervical cancer progression. PLoS One (2009) 2.21
Ribonucleotide reductase: regulation, regulation, regulation. Trends Biochem Sci (1992) 2.07
LKB1 and AMPK family signaling: the intimate link between cell polarity and energy metabolism. Physiol Rev (2009) 1.93
CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo. Clin Cancer Res (2007) 1.58
High-throughput, accurate mass metabolome profiling of cellular extracts by flow injection-time-of-flight mass spectrometry. Anal Chem (2011) 1.51
LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell (2012) 1.49
TP53 mutations in nonsmall cell lung cancer. J Biomed Biotechnol (2011) 1.46
Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene (2001) 1.41
Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Ann Oncol (2000) 1.40
Phosphorylation of deoxycytidine analog monophosphates by UMP-CMP kinase: molecular characterization of the human enzyme. Mol Pharmacol (1999) 1.27
Presence and consequence of uracil in preneoplastic DNA from folate/methyl-deficient rats. Carcinogenesis (1997) 1.11
Human dTMP kinase: gene expression and enzymatic activity coinciding with cell cycle progression and cell growth. DNA Cell Biol (1994) 1.03
Human AP endonuclease (APE1) demonstrates endonucleolytic activity against AP sites in single-stranded DNA. DNA Repair (Amst) (2004) 1.02
Tumor cells require thymidylate kinase to prevent dUTP incorporation during DNA repair. Cancer Cell (2012) 0.98
Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/p21 pathway is functional. Oncogene (2011) 0.97
Disintegration of nascent replication bubbles during thymine starvation triggers RecA- and RecBCD-dependent replication origin destruction. J Biol Chem (2012) 0.96
Synthetic lethality by lentiviral short hairpin RNA silencing of thymidylate kinase and doxorubicin in colon cancer cells regardless of the p53 status. Cancer Res (2008) 0.90
Molecular cloning and expression of the human deoxythymidylate kinase gene in yeast. Nucleic Acids Res (1991) 0.89
Phenotypic enhancement of thymidylate synthetase pathway inhibitors following ablation of Neil1 DNA glycosylase/lyase. Cell Cycle (2010) 0.88
Pathways of resistance to thymineless death in Escherichia coli and the function of UvrD. Genetics (2011) 0.87
Strain differences in mice highlight the role of DNA damage in neoplasia induced by low dietary folate. J Nutr (2008) 0.86
Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 49.82
A draft sequence of the rice genome (Oryza sativa L. ssp. indica). Science (2002) 42.78
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
AKT/PKB signaling: navigating downstream. Cell (2007) 31.26
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Resveratrol improves health and survival of mice on a high-calorie diet. Nature (2006) 20.91
International network of cancer genome projects. Nature (2010) 20.35
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2009) 19.65
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell (2006) 18.81
Selective inhibition of BET bromodomains. Nature (2010) 18.79
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature (2008) 18.20
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet (2006) 17.19
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med (2011) 16.94
AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell (2008) 16.72
Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res (2011) 16.53
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res (2003) 15.74
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell (2008) 14.18
Bis[bis(methoxycarbimido)amine-kappa2N,N']bis(perchlorato-kappaO)copper(II) bis[bis(methoxycarbimido)amine-kappa2N,N']bis(methanol-kappaO)copper(II) bis(perchlorate) methanol disolvate. Acta Crystallogr C (2006) 14.17
Lung cancer. N Engl J Med (2008) 13.49
WEGO: a web tool for plotting GO annotations. Nucleic Acids Res (2006) 13.06
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst (2005) 13.00
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem (2009) 12.73
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science (2005) 12.35
The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A (2004) 12.30
Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. Genes Dev (2005) 12.15
Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature (2006) 12.13
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell (2002) 11.65
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature (2011) 11.31
Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science (2010) 11.29
Sequencing of 50 human exomes reveals adaptation to high altitude. Science (2010) 11.27
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell (2010) 11.20
Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci U S A (2004) 10.78
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest (2008) 10.74
Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell (2006) 10.10
Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med (2014) 9.94
Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature (2008) 9.77
ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol (2012) 9.76
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol (2008) 9.43
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res (2008) 9.29
Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer (2009) 9.26
Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature (2006) 9.20
p16INK4a induces an age-dependent decline in islet regenerative potential. Nature (2006) 9.09
The regulation of INK4/ARF in cancer and aging. Cell (2006) 8.75
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell (2009) 8.64
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 8.64
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer (2009) 8.43
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med (2012) 8.41
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature (2008) 8.38
Ink4a/Arf expression is a biomarker of aging. J Clin Invest (2004) 8.30
Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev (2003) 8.27
Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev (2006) 8.26
Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol (2003) 8.25
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A (2007) 8.23
The genome of the cucumber, Cucumis sativus L. Nat Genet (2009) 8.19
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A (2008) 8.08
Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. Nature (2006) 8.06
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature (2011) 8.03
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell (2005) 7.99
An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science (2012) 7.94
Bidirectional transport of amino acids regulates mTOR and autophagy. Cell (2009) 7.88
LKB1 modulates lung cancer differentiation and metastasis. Nature (2007) 7.80
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell (2010) 7.78
The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell (2004) 7.77
The Genomes of Oryza sativa: a history of duplications. PLoS Biol (2005) 7.67
Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science (2004) 7.63